Technical analysis of Alterity Therapeutics Limited (ATHE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease.
Price Performance
| 1 month | -15.57% |
| 3 months | -21.11% |
| Year-to-date | +25.00% |
| 1 year | -13.87% |
| 3 years | +48.07% |
| 5 years | -70.38% |
52-Week Range
| 52-week High | $5.89 |
| 52-week Low | $2.66 |
| Avg Volume (90d) | 37K |
Technical Indicators
| SMA 50 | $4.62 |
| SMA 200 | $4.02 |
| Beta | -0.07 |
| 30-day Volatility (annualised) | 69.8% |
| Price vs SMA 50 | -16.6% |
| Price vs SMA 200 | -4.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $4.21 | |
| 2025-11 | $3.60 | -14.5% |
| 2025-12 | $3.08 | -14.4% |
| 2026-01 | $3.17 | +2.9% |
| 2026-02 | $3.44 | +8.5% |
| 2026-03 | $3.48 | +1.2% |
| 2026-04 | $4.54 | +30.5% |
| 2026-05 | $4.12 | -9.3% |
| 2026-06 | $5.37 | +30.3% |
| 2026-07 | $4.42 | -17.7% |
| 2026-08 | $4.49 | +1.6% |
| 2026-09 | $3.85 | -14.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $3.85 |
| Market Cap | $65M |
| Exchange | NASDAQ |
| Country | AU |
Valuation Ratios
| Price / Book | 2.73 |
| EV / EBITDA | -3.58 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 14.52 |